Pay in 4 interest-free payments of $6.67 Learn more
Ships within 48 hours · Estimated delivery Sep 7 - Sep 12
Notably, many trial participants had sedentary lifestyles or reported minimal exercise, yet still achieved these results, confirming that appetite suppression alone drives significant metabolic change
Secondary efficacy endpoints included but were not limited to change in body weight
According to research, on average, people taking tirzepatide (the active ingredient in Zepbound) can lose around 20.9% of their starting body weight
Diarrhea Diarrhea affects about 29.7% of semaglutide 2.4 mg users in the STEP trials versus 15.9% on placebo
Data in human subjects are mostly observational and lack randomized controlled trials
US$ 28.73
US$ 23.94
US$ 21.74
US$ 25.10
US$ 21.16
